Communication Breakdown: Why Soft Skills Are More Important Than Ever in Life Sciences

Jan 14, 2026 | Pharma

Image Source: Resilience Launch Event
Written by: Contributor
On behalf of: Life Science Daily News

We all know or work with people who can be difficult to deal with and even talk to, and we all know or work with other people who are a joy to be around and who make the working day a little brighter.

Some of those difficult people will be highly competent in their field; their technical knowledge will be deeper than most – and they will know it.

But is technical competence enough? Do organisations need only that in order to thrive, or are soft skills (like communication, teamwork, and leadership) equally important?

A recent report from Harvard Business Review concludes that soft skills help workers reach the highest levels of professional attainment.

The report notes;

“Put simply, as technical complexity rises, the glue that keeps talent productive is social skill—communication, empathy, conflict resolution, and the ability to coordinate diverse expertise”.

Soft skills, then, are those personal attributes, traits, and abilities that determine how you interact and work with others – helping you to navigate the complexities and challenges of the workplace, like difficult personalities, conflict, and shifting priorities.

They are vital for effective collaboration and, unsurprisingly, highly valued by employers.

In this article we look at how organisations are embracing new technologies, such as VR and AI, to help develop those soft skills; and we highlight the issues faced by the medicines manufacturing sector to illustrate the importance of soft skills in life sciences.

Life Skills

The life sciences sector is a priority for the UK Government and a huge employer of highly-skilled scientists and engineers, along with many others working in support or administrative roles.

But there is a critical skills shortage in some areas; for example, one report calculates that 70,000 new and 75,000 replacement jobs will be needed in medicines manufacturing in the next 10 years, as new medicines are approved that require complex handling and processing.

The government has responded to this by creating Resilience, the UK’s Medicines Manufacturing Skills Centre of Excellence; it is a 2-year, £4.5 million programme designed to excite, engage, and attract young people to work in the sector, and it uses advanced VR technology to deliver core laboratory and manufacturing skills.

Critically, it also uses AI-powered VR technology to develop soft skills, creating and learning from customisable roleplay.

VR offers many benefits for this kind of learning; users can be put into highly typical real life scenarios, such as a difficult conversation or job interview, where they interact with virtual avatars. Crucially, they can replay the scenario over and over, trying new approaches and building confidence.

AI tools can analyse users’ behaviours and actions (speech, body language, decisions) and provides immediate insights to guide improvements.

Perhaps most importantly, users can literally try seeing the scenario from other perspectives (for example, a colleague’s), which creates empathy and allows the user to see how they come across to a third party.

While the idea of watching ourselves back, for example in an interview, is enough to make most people squirm, it can reveal aspects of our behaviour (mannerisms, delivery, and body language, for example) that we’re likely unaware of.

Finally, VR training can be delivered anywhere and scaled at will, so is highly cost-effective.

Conclusions

Soft skills matter. They foster teamwork, collaboration, and a healthy, happy, workplace.

Most importantly, they can be learned and developed; AI and VR are powerful tools for training in soft skills.

Of course, not every company needs to be so reliant on soft skills; start-ups may need ‘instant’ technical expertise, and high-turnover operations may simply not care, but for the vast majority of workplaces soft skills really matter – a lot.

Given the critical skills shortages in some parts of the UK’s life sciences sector, it is vitally important that we not only find highly qualified scientists and engineers, but also ensure that they are ready to work in and contribute to a collaborative, supportive, respectful, and trusting environment.

Communication is the core skill that underpins everything, and it cuts both ways; articulating your point clearly is vital, but so is actively listening.

As George Bernard Shaw put it;

“The single biggest problem in communication is the illusion that it has taken place.”

About Resilience

Resilience is the UK Medicines Manufacturing Skills Centre of Excellence. It is a £4.3 million programme funded by the Office for Life Sciences, part of the UK Government’s Department for Science, Innovation & Technology, and managed through Innovate UK.

The two-year programme, which started in April 2024, uses virtual reality to train medicine makers in core skills which would be impractical, disruptive, and expensive to gain in the real world.

Partner organisations across the UK delivering the programme include the University of Birmingham, University College London (UCL), Teesside University, Heriot-Watt University and Britest. Professor Ivan Wall of the University of Birmingham and Professor Gary Lye of UCL are co-directors.

As well as bridging the skills gap, Resilience is helping the NHS to meet its long-term goal of achieving net zero. 25% of NHS emissions are in the supply chain, and VR will help the industry deliver net zero medicines manufacturing by reducing laboratory waste.

Written by Ivan Wall
Professor of Regenerative Medicine at the University of Birmingham and co-director of Resilience, the UK’s Medicines Manufacturing Skills Centre of Excellence

    References: Incorporated into the article.

    Articles that may be of interest

    J&J Axes Eczema Drug From $1.25B Acquisition

    J&J Axes Eczema Drug From $1.25B Acquisition

    Johnson & Johnson has discontinued development of an eczema treatment that was a central asset in a biotechnology acquisition valued at up to 1.25 billion US dollars, following a recent internal portfolio review. The decision highlights the ongoing scientific and...

    read more

    Articles that may be of interest

    J&J Axes Eczema Drug From $1.25B Acquisition

    J&J Axes Eczema Drug From $1.25B Acquisition

    Johnson & Johnson has discontinued development of an eczema treatment that was a central asset in a biotechnology acquisition valued at up to 1.25 billion US dollars, following a recent internal portfolio review. The decision highlights the ongoing scientific and...

    read more